Topical Vitamin D3 approved by FDA for Psoriasis
February 4th, 2009, by Digital Davo | in the news, topicals
The FDA has recently approved Vectical (topcial vitamin D3 from Galderma) for the treatment of plaque psoriasis. The active ingredient of Vectical is known as calcitrol and is a naturally occurring form of vitamin D3. Calcitrol has been shown safe to use for extended periods up to 52 weeks and also on sensitive skin fold areas. Users of Vectical should avoid exposure to the sun.

The mechanism of action of calcitrol in the treatment of psoriasis has not been established but Vitamin D3 has been shown to contribute "to the regulation of development and function of mast cells, which play a critical role in several inflammatory disorders”. Also it seems to have important immunomodulating effects, both reducing levels of pro-inflammatory cytokines and increasing levels of anti-inflammatory cytokines. See RSRP: Vitamin D3 for more information.

The Vectical prescribing information says that it should not be applied to the eyes, lips or facial skin. This may well limit the applicability of Vectical to treat rosacea of course. With all of the interest in Vitamin D3, this new product does look interesting though.